Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. Issue 4 (July 2021)

• Record Type: Journal Article
• Authors: Quhal, Fahad; Mori, Keiichiro; Remzi, Mesut; Fajkovic, Harun; Shariat, Shahrokh F.; Schmidinger, Manuela
• Is Part Of: Current opinion in urology. Volume 31:Issue 4(2021)
• Publication Date: 2021-07
• Subjects: adverse events -- first-line -- network meta-analyses -- randomized controlled trial -- renal cell carcinoma -- systemic therapy; Urology -- Periodicals; Review Literature -- Bibliography; Review Literature -- Periodicals; Male Urogenital Diseases -- Bibliography; Male Urogenital Diseases -- Periodicals; Female Urogenital Diseases -- Bibliography; Female Urogenital Diseases -- Periodicals; Urologic Diseases -- Bibliography; Urologic Diseases -- Periodicals; Periodicals; 616.6005
• DOI: 10.1097/MOU.0000000000000889
• Languages: English
• ISSNs: 1473-6586

Abstract

Abstract : Purpose of review: To compare the safety profiles of systemic immune checkpoint inhibitor-based combination therapies that were evaluated in the first-line setting of the management of patients with advanced or metastatic renal cell carcinoma (mRCC). Recent findings: Six phase III randomized control trials comparing first-line immune-based combination therapies to sunitinib in previously untreated patients with mRCC. Network meta-analyses were conducted to compare treatment-related adverse events (TRAEs), treatment discontinuation, and treatment-related mortality. Summary: Lenvatinib plus pembrolizumab was associated with the highest likelihood of grade ≥3 TRAEs, and treatment discontinuation rates. Nivolumab plus ipilimumab was associated with the lowest rates of grade ≥3 TRAEs. However, it was associated with a higher likelihood of endocrine-related adverse events (AEs). A higher likelihood of high-grade diarrhea was associated with pembrolizumab plus axitinib and avelumab plus axitinib. All combinations showed low rates of hematological AEs. Abstract : Supplemental Digital Content is available in the text